Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Support for fast pharmaceutical regulatory approval

Our intelligence on approved and pipeline drugs, plus regulatory information on devices/diagnostics help you plan your route to commercial success.

Your window on the pipeline

To achieve commercial success, you need to connect successful approved drugs and mid-to-late stage pipeline drugs to the underlying trial information. You’ll also want to focus in on the best trial designs and comparator arms that have met with success across target markets.

What we offer

Our solutions give you the tools and intelligence to quickly build up a landscape of approved and pipeline drugs for a disease of interest. We cover where drugs have been approved or are in development, and timeline projections for clinical trials and time to regulatory approvals.
You’ll also be able to find comprehensive, accurate regulatory information on devices/diagnostics, particularly for FDA and CE Mark approvals.
Plus, you can save time filtering information by mechanism of action or drug class.

How it helps

We’ll help you:

Stay up to date with new regulatory trends/changes in pharma and medtech
Anticipate label claims of your competitors and ensure your product has a strong and promising future in the market
Learn from the pitfalls of terminated trials for similar drugs
Understand successful (and unsuccessful) strategies to achieve priority regulatory designations, that you can incorporate into your own development plans
Tap into the industry’s top analysts to help with your research needs

Relevant products

Biomedtracker: see the drug development process through analysts’ eyes

Real-time tracking and analysis of the drug development pipeline

Key benefits:

Market Events & Catalysts
Likelihood of Approval
Deals Coverage

Pink Sheet: global policy and regulatory coverage

Unparalleled access to global pharma regulatory and compliance intelligence and expertise.

Key benefits:

Get a global view
Go beyond the news
Hear from news makers

HBW Insight: Health, Beauty and Wellness

The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.

Key benefits:

Get a global view
Be the first to know
Go beyond the news

View all content

Citeline, Biomedtracker, Pharma Consulting, Datamonitor Heal...

COVID-19 24 hour webinar recordings

Catch up on any missed COVID-19 24 hour webinar sessions

Topic Cardiovascular Coronavirus

Full video
Pink Sheet

Patient-Reported Data In COVID-Impacted Trials: US FDA Cautions Against Missing Data, Potential Bias

Considerations for switching from in-person to remote collection of patient- and observer-reported outcomes addressed in latest update to Q&A guidance, which also discusses Part 11 compliance requirements in the context of the pandemic and electronic collection of informed consent through MyStudies app.

Topic Coronavirus Clinical Trials

View article
Generics Bulletin

EU Sees Drug Shortage Risk From COVID-19 Second Wave

A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

Topic Coronavirus Distribution

View article
Generics Bulletin

Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.

Topic Coronavirus

View article
Generics Bulletin

Remdesivir Compulsory Licensing Is A Dead End For Europe

In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.

Topic Coronavirus Intellectual Property Policy & Regulation

View article
Generics Bulletin

Remdesivir Licensing Agreements for Generics Companies

Keep up with crucial developments in the generics industry as Gilead signs non-exclusive, voluntary licensing agreements with several generics manufacturers in an effort to more widely manufacture and distribute the COVID-19 drug remdesivir, used to help patients recover from severe coronavirus infections faster.

Topic Drug Development Landscape

Single report
HBW Insight

Italy's Supplements Market Gets Big Boost From COVID After Solid 2019

Coronavirus pandemic drove up sales of vitamin C supplements and other immunity boosters in Italy in the opening three months of the year.

Topic Coronavirus Dietary Supplements

View article
HBW Insight

No Evidence That Vitamin D Prevents Or Treats COVID-19

UK's NICE reviews whether Vitamin D can prevent or treat COVID-19, finds evidence wanting.

Topic Coronavirus Dietary Supplements

View article
HBW Insight

Nurofen Ad Pulled In NZ For Irresponsible Message During COVID Pandemic

Reckitt Benckiser's TV ad for Nurofen in New Zealand drew numerous complaints for being "socially irresponsible" during the COVID-19 pandemic.

Topic Coronavirus Advertising, Marketing & Sales

View article
HBW Insight

Probiotics’ Efficacy Too Specific For General Look In ’60 Minutes’ Segment Critical Of Category

Assertions that no convincing evidence supports that probiotics available in the US treat symptoms of diarrhea, irritable bowel syndrome or allergies look at the category as a whole and not individual strains shown to help with specific conditions, say consumer health industry groups.

Topic Coronavirus Dietary Supplements Research & Development

View article
Pink Sheet

UK Uses Local Outbreak Data To Target Coronavirus Vaccine Trials

The UK Vaccine Taskforce is helping to troubleshoot for COVID-19 candidates including in clinical trials and manufacturing scale-up.

Topic Coronavirus Clinical Trials Vaccines

View article
Pink Sheet

Europe’s Ad Hoc Pandemic Response Highlights Supply Chain Weaknesses

Panelists at a recent virtual session of the DIA’s Europe 2020 conference identified the positive and negative aspects of Europe’s response to the pandemic, and suggested ways of avoiding shortages and making the supply chain more resilient in the event of future crises.

Topic Coronavirus Distribution EU

View article
Datamonitor Healthcare, Biomedtracker

COVID-19 and the impact on the clinical trial space

The effect of COVID-19 on clinical trials, the industry response, and the return to full operations

Topic Coronavirus Clinical Trials

View white paper
HBW Insight

Health, Beauty and Wellness Coronavirus Coverage

The COVID-19 pandemic has impacted the consumer health and beauty products industries in different ways, and HBW Insight covers it all. We deliver all the latest regulatory, legislative, legal and commercial developments across the over-the-counter medicine, dietary supplement and the cosmetics sectors to keep you informed and strategically on target.

Topic Coronavirus

Single report
Pink Sheet

New Leader & Reorgs at Key Regulatory Agencies

Pink Sheet invites you to go inside the recent personnel changes at key regulatory agencies around the globe – including US FDA, EMA, and England’s NICE – and how these new appointments will likely influence future regulation of the biopharma industry.

Topic Regulation

Single report